Medicinal composition for treating impotence

A composition and drug technology, applied in the directions of drug combination, drug delivery, drug formulation, etc., can solve the problem of no corresponding prompts, no indication of the therapeutic effect of idenafil dose, etc.

Inactive Publication Date: 2007-06-13
刘宝顺
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it does not indicate the dosage of edenafil with outstanding therapeutic effects, nor does it indicate the corresponding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating impotence

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1. Determination of Edina nonspecificity

[0037] cGMP Enzymeimmunoassay Biotrak TM (EIA) System (Amersham company RPN226, 43A, W306740) detects different concentrations of edenafil citrate in vitro (10 -4 mol / L, 10 -5 mol / L, 10 -6 mol / L, 10 -7 mol / L, 10 -8 mol / L, 10 -9 mol / L, 10 -10 mol / L, 10 -11 mol / L, 10 -12 mol / L, prepared from white crystalline powder of ardenafil citrate with a content of 99.99%) to inhibit the degradation of cGMP by PDE3A, PDE3B, PDE5 and PDE6.

[0038] Determination of the Inhibitory Effect of Aldenafil Citrate on PDE3A and PDE3B

[0039] Draw a certain amount of human PDE3A (Orbigen, Cat No: bvc-10185, Lot No.10689) and human PDE3B (Orbigen, Cat No: bvc-10186, Lot No.10690), respectively, and dilute the corresponding volume of PBS to make the final concentration 1u / μl. 3u of PDE3A and PDE3B were co-acted with 3200 fmol (50 μl) of cGMP. After acting at 30°C for 20 minutes, 100 μl was added to the assay well, and 100 μl of an...

Embodiment 2

[0050] Example 2: Effects of Aldenafil on Penile Erectile Function Caused by Electrical Stimulation of Peripheral Pelvic Nerves in Anesthetized Dogs

[0051] Standard methods known to those skilled in the art were used to study the effect of edenafil on penile erectile function induced by electrical stimulation of peripheral pelvic nerves in anesthetized dogs. The results showed that, under the condition of no stimulation, edenafil had no obvious effect on intracavernous pressure. Pelvic nerve stimulation (PNS) in the range of 2.5-20Hz, aldenafil 0.3, 1, 3mg / kg can significantly increase penile erectile function, increase penile intracavernosal pressure (ICP), about 30-90 minutes after administration The effect reached its peak. And there is an obvious dose-effect relationship on the effect of electrical stimulation on the peripheral pelvic nerve of anesthetized dogs to cause penile erection. At 2.5Hz, the maximum increase percentages of erectile function index of the three ...

Embodiment 3

[0054] Embodiment 3: clinical efficacy test

[0055] A randomized, double-blind, multi-center, parallel controlled trial method was used to study the clinically effective dosage of different doses of Aldenafil citrate tablets (30mg, 60mg) and placebo in the treatment of male erectile dysfunction, and to further evaluate its safety and efficacy.

[0056]Methods: This clinical trial was carried out in 5 national clinical base test centers, and a total of 250 patients were randomly selected, including 84 cases in the 30mg group and 83 cases in the 60mg group. All 250 subjects, after a 4-week screening preparation period, were randomly and double-blindly entered into 3 parallel dose groups (30mg, 60mg and placebo groups), and received 4 weeks of treatment. The main evaluation indicators of effectiveness were the erectile function score in IIEF at the end of treatment, the style of the patient's sexual life diary (SEP) and the percentage of 3 answers "yes". The safety evaluation ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a medicine composition for curing impotence. Said medicine composition includes edenaphy. Said medicine composition can be made into various dosage forms of tablet, capsule, powder, granules and solution, etc.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition for treating impotence, in particular to edenafil (5-[2- Ethoxy-5-(cis-2,6-dimethylpiperazine-4-sulfonyl)phenyl]-1-methyl-3-n-propyl-7,6-dihydro-1H-pyridine Azolo[4,3-d]pyrimidin-7-one) pharmaceutical composition. Background technique [0002] The applicant disclosed in WO 03 / 016313 the compound 5-[2-ethoxy-5-(cis-2,6-dimethylpiperazine-4-sulfonyl)phenyl]- 1-methyl-3-n-propyl-7,6-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one (namely Aildenafil, the English name is Aildenafil), and in Claim 5 claims a pharmaceutical composition for treating impotence, which contains an effective amount of the compound or its pharmaceutically acceptable salt or its conformational isomer and a pharmaceutically acceptable carrier as an active ingredient. However, the application only verified the therapeutic effect of the compound on the rat model when the dosage was 24 mg / kg and 12 mg / kg in its description. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61K9/00A61P15/10
Inventor 刘宝顺
Owner 刘宝顺
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap